Lexaria Bioscience Corp (LEXX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lexaria Bioscience Corp (LEXX) has a cash flow conversion efficiency ratio of -0.348x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.16 Million) by net assets ($6.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LEXX net asset quality score to measure how much of total assets are equity-financed.
Lexaria Bioscience Corp - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Lexaria Bioscience Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Lexaria Bioscience Corp to evaluate the quality of earnings relative to operating cash generation.
Lexaria Bioscience Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lexaria Bioscience Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biomind Labs Inc
NEO:BMND
|
0.028x |
|
Agrogeneration
PA:ALAGR
|
-0.030x |
|
Desenio Group AB
ST:DSNO
|
0.087x |
|
Takuni Group Public Company Limited
BK:TAKUNI
|
0.475x |
|
Sweden BuyersClub AB
ST:BUY
|
0.227x |
|
Guardforce AI Co Ltd
NASDAQ:GFAI
|
0.022x |
|
Huge Group Ltd
JSE:HUG
|
-0.013x |
|
Peregrine Gold Ltd
AU:PGD
|
-0.334x |
Annual Cash Flow Conversion Efficiency for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual cash flow conversion efficiency of Lexaria Bioscience Corp from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Lexaria Bioscience Corp.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $2.60 Million | $-10.45 Million | -4.015x | -520.13% |
| 2024-08-31 | $7.66 Million | $-4.96 Million | -0.647x | +70.49% |
| 2023-08-31 | $2.68 Million | $-5.88 Million | -2.194x | -243.26% |
| 2022-08-31 | $7.63 Million | $-4.88 Million | -0.639x | -109.32% |
| 2021-08-31 | $13.06 Million | $-3.99 Million | -0.305x | +71.05% |
| 2020-08-31 | $2.48 Million | $-2.62 Million | -1.055x | +12.57% |
| 2019-08-31 | $2.49 Million | $-3.01 Million | -1.207x | -14.45% |
| 2018-08-31 | $2.39 Million | $-2.52 Million | -1.054x | -88.77% |
| 2017-08-31 | $2.77 Million | $-1.55 Million | -0.559x | +92.58% |
| 2016-08-31 | $87.76K | $-660.86K | -7.531x | -229.41% |
| 2015-08-31 | $656.60K | $-1.50 Million | -2.286x | -1594.78% |
| 2014-08-31 | $2.10 Million | $321.00K | 0.153x | 0.00% |
| 2013-08-31 | $2.10 Million | $321.00K | 0.153x | +6.02% |
| 2012-08-31 | $2.23 Million | $321.00K | 0.144x | +182.41% |
| 2011-08-31 | $2.66 Million | $135.94K | 0.051x | +11.09% |
| 2010-08-31 | $2.39 Million | $109.84K | 0.046x | +130.70% |
| 2009-08-31 | $2.21 Million | $-330.34K | -0.150x | -913.10% |
| 2008-08-31 | $2.46 Million | $-36.40K | -0.015x | -272.88% |
| 2007-08-31 | $3.39 Million | $29.04K | 0.009x | +102.76% |
| 2006-08-31 | $704.55K | $-218.56K | -0.310x | -120.33% |
| 2005-08-31 | $1.09 Million | $-153.38K | -0.141x | -- |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more